John E. Harris
John E. Harris
Verified email at
Cited by
Cited by
CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo
M Rashighi, P Agarwal, JM Richmond, TH Harris, K Dresser, MW Su, ...
Science translational medicine 6 (223), 223ra23-223ra23, 2014
乳鼠心肌提取 HHS Public Access
M Rashighi, JE Harris
Physiol Behav 176 (3), 139-148, 2017
New discoveries in the pathogenesis and classification of vitiligo
M Rodrigues, K Ezzedine, I Hamzavi, AG Pandya, JE Harris, ...
Journal of the American Academy of Dermatology 77 (1), 1-13, 2017
A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin
JE Harris, TH Harris, W Weninger, EJ Wherry, CA Hunter, LA Turka
Journal of Investigative Dermatology 132 (7), 1869-1876, 2012
Vitiligo: mechanisms of pathogenesis and treatment
ML Frisoli, K Essien, JE Harris
Annual review of immunology 38, 621-648, 2020
Vitiligo pathogenesis and emerging treatments
M Rashighi, JE Harris
Dermatologic clinics 35 (2), 257-265, 2017
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ...
The Lancet 400 (10349), 359-368, 2022
Innate immune mechanisms in vitiligo: danger from within
JM Richmond, ML Frisoli, JE Harris
Current opinion in immunology 25 (6), 676-682, 2013
Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
JE Harris, M Rashighi, N Nguyen, A Jabbari, G Ulerio, R Clynes, ...
Journal of the American Academy of Dermatology 74 (2), 370-371, 2016
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
LY Liu, JP Strassner, MA Refat, JE Harris, BA King
Journal of the American Academy of Dermatology 77 (4), 675-682. e1, 2017
Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo
JM Richmond, JP Strassner, L Zapata Jr, M Garg, RL Riding, MA Refat, ...
Science Translational Medicine 10 (450), eaam7710, 2018
Current and emerging treatments for vitiligo
M Rodrigues, K Ezzedine, I Hamzavi, AG Pandya, JE Harris, ...
Journal of the American Academy of Dermatology 77 (1), 17-29, 2017
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
D Rosmarin, AG Pandya, M Lebwohl, P Grimes, I Hamzavi, AB Gottlieb, ...
The Lancet 396 (10244), 110-120, 2020
Immunology and skin in health and disease
JM Richmond, JE Harris
Cold Spring Harbor perspectives in medicine 4 (12), a015339, 2014
Human Slug is a repressor that localizes to sites of active transcription
K Hemavathy, SC Guru, J Harris, JD Chen, YT Ip
Molecular and cellular biology, 2000
A network of high-mobility group box transcription factors programs innate interleukin-17 production
N Malhotra, K Narayan, OH Cho, KE Sylvia, C Yin, H Melichar, ...
Immunity 38 (4), 681-693, 2013
Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells
JE Harris, KD Bishop, NE Phillips, JP Mordes, DL Greiner, AA Rossini, ...
The Journal of Immunology 173 (12), 7331-7338, 2004
Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease
JM Richmond, DS Bangari, KI Essien, SD Currimbhoy, JR Groom, ...
Journal of Investigative Dermatology 137 (2), 350-358, 2017
Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo
M Rashighi, JE Harris
Annals of translational medicine 3 (21), 2015
CXCR4 identifies transitional bone marrow premonocytes that replenish the mature monocyte pool for peripheral responses
SZ Chong, M Evrard, S Devi, J Chen, JY Lim, P See, Y Zhang, JM Adrover, ...
Journal of Experimental Medicine 213 (11), 2293-2314, 2016
The system can't perform the operation now. Try again later.
Articles 1–20